ARCIS BIOTECHNOLOGY
Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles .
ARCIS BIOTECHNOLOGY
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical
Founded:
2009-01-01
Address:
Warrington, Warrington, United Kingdom
Country:
United Kingdom
Website Url:
http://www.arcisbio.com
Total Employee:
1+
Status:
Active
Total Funding:
6.6 M GBP
Technology used in webpage:
Domain Not Resolving Person Schema Facebook Sharer Gravatar Profiles CrUX Top 50m CrUX Dataset Pinterest Reddit
Similar Organizations
Exprimo
Exprimo is focuses on the application of population PK, advanced PK/PD and drug-disease modelling & simulation.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Capital Cell
Capital Cell investment in Venture Round - Arcis Biotechnology
Fund Twenty8
Fund Twenty8 investment in Equity Crowdfunding - Arcis Biotechnology
Calculus Capital
Calculus Capital investment in Seed Round - Arcis Biotechnology
Calculus Capital
Calculus Capital investment in Seed Round - Arcis Biotechnology
Official Site Inspections
http://www.arcisbio.com
- Host name: 104.21.96.1
- IP address: 104.21.96.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arcis Biotechnology"
Leadership Team - Arcus Biosciences
Ms. Jarrett is an accomplished executive in the healthcare and technology industries. She most recently served as Vice President of Corporate Development and Capital Markets of Uber …See details»
Arcus Biosciences | Pursuit of Cures for Cancer
Arcus is a biopharmaceutical company aiming to bring together scientists, physicians & advisors to focus on developing best-in-class cancer therapies.See details»
Arcus Biosciences - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 510-694-6200 Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the …See details»
Arcus Biosciences - Investors & Media - Corporate Governance
He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen’s large and small molecule drug discovery efforts. Prior …See details»
Arcus Biosciences - LinkedIn
Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to …See details»
Arcus Biosciences - Overview, News & Similar companies - ZoomInfo
Oct 23, 2024 Arcus Biosciences contact info: Phone number: (510) 694-6200 Website: www.arcusbio.com What does Arcus Biosciences do? Founded in 2015, Arcus Biosciences is …See details»
Gilead and Arcus Announce Amended Collaboration …
Jan 29, 2024 FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and …See details»
Board of Directors - Arcus Biosciences
During his 17-year tenure at Amgen, Dr. Lacey oversaw Amgen’s Discovery Research organization during a key period in the company’s history, leading more than 1,200 scientists across a portfolio of drug discovery and development …See details»
Arcus Biosciences - Arcus Biosciences Appoints David Lacey, M.D., …
May 26, 2020 Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, …See details»
Arcus Biosciences to Present First Clinical Data from ARC-20
Oct 9, 2024 Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that …See details»
Data Disclosure and Clinical Transparency Policy | Arcus Trials
The decision to grant a request for clinical trial data shall be the sole discretion of Arcus Biosciences. Arcus Biosciences may consider all relevant information in making its decision, …See details»
Arcus Biosciences - Arcus Biosciences Appoints Internationally ...
Oct 28, 2019 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni …See details»
Scientific Advisory Board - Arcus Biosciences
During his 17-year tenure at Amgen, Dr. Lacey oversaw Amgen’s Discovery Research organization during a key period in the company’s history, leading more than 1,200 scientists …See details»
Our Science | Clinical Pipeline - Arcus Biosciences
In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.The parties will co-develop Gilead …See details»
Arcus Biosciences - Arcus Biosciences Presents Promising Initial …
Jan 15, 2021 - 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8, comparing favorably to the current standard-of …See details»
Print or download - trials.arcusbio.com
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.See details»
Arcus Founders Talk Strategy and Legacy | Arcus Biosciences
The company is confident in its strategy to date and is now focused on building a long-term independent and commercial organization. “As we look back on the choices we made five or …See details»
Arcus Biosciences Reports Third Quarter 2022 Financial Results …
Nov 2, 2022 HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated …See details»
Arcus Biosciences Reports Third Quarter 2023 Financial Results …
Nov 7, 2023 HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated …See details»